A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma With DNA-Repair Defects

PRIMARY OBJECTIVES: I. To evaluate the efficacy of olaparib in two cohorts of patients with metastatic/advanced urothelial carcinoma (UC) pre-selected by deoxyribonucleic acid (DNA)-repair defects as measured by overall response rate (ORR). SECONDARY OBJECTIVES: I. To describe the effect of therapy...

Full description

Bibliographic Details
Other Involved Persons: National Cancer Institute (NCI)
Format: eBook
Published: Bethesda (Maryland) : ClinicalTrials.gov March 15, 2019
Item Description:Copyright: Source: ClinicalTrials.gov (no modifications made)
Copyright: ClinicalTrials.gov processed this data on May 06, 2019
Copyright: Last update posted on ClinicalTrials.gov: March 15, 2019
Copyright: Last updated: 2019-05-06
Physical Description:Online-Ressource
QR Code: Show QR Code